In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Omar Alhalabi, MD
Advertisement
Articles by Omar Alhalabi, MD
Advertisement
Latest Updated Articles
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma
3
Pyrotinib Combo Sustains Survival Benefits in HER2+ Breast Cancer Trial
4
Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma
5